Superinfection with Enterococcus faecalis during quinupristin/dalfopristin therapy.
Chow
J W
JW
Department of Veterans Affairs Medical Center, Detroit, Michigan, USA.
Davidson
A
A
Sanford
E
E
Zervos
M J
MJ
D000328:Adult; D000368:Aged; D000667:Ampicillin / Q000494:pharmacology / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use*; D001026:Coronary Artery Bypass / Q000009:adverse effects; D003922:Diabetes Mellitus, Type 1 / Q000150:complications / Q000628:therapy; D004342:Drug Hypersensitivity / Q000175:diagnosis / Q000382:microbiology; D004696:Endocarditis / Q000150:complications / Q000188:drug therapy / Q000382:microbiology; D013293:Enterococcus faecalis; D005839:Gentamicins / Q000494:pharmacology; D016908:Gram-Positive Bacterial Infections / Q000175:diagnosis*; D006801:Humans; D008297:Male; D008712:Methicillin / Q000494:pharmacology / Q000627:therapeutic use; D016106:Methicillin Resistance; D008826:Microbial Sensitivity Tests; D010406:Penicillins / Q000494:pharmacology / Q000627:therapeutic use; D006435:Renal Dialysis / Q000009:adverse effects; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013211:Staphylococcus aureus / Q000187:drug effects; D015163:Superinfection / Q000175:diagnosis*; D014640:Vancomycin / Q000009:adverse effects / Q000494:pharmacology; D014769:Virginiamycin / Q000009:adverse effects* / Q000627:therapeutic use*; D014946:Wound Infection / Q000188:drug therapy
D000900:Anti-Bacterial Agents; D005839:Gentamicins; D010406:Penicillins; D014769:Virginiamycin; C062940:quinupristin-dalfopristin; D014640:Vancomycin; D000667:Ampicillin; D008712:Methicillin